For Physicians. By Physicians.™
For Physicians. By Physicians.™
Multiple guidelines have been released to decrease severe morbidity and mortality associated with preeclampsia but data remains limited as to impact of these recommendations on adverse events. This study by Shields et al. (AJOG, 2017) aimed to determine if standardized guideline-based protocols to treat severe hypertension/preeclampsia are associated with improved outcomes.
Multicentered, Prospective Quality Improvement Project. The standardized protocol included IV anti-hypertensive medication and magnesium sulfate when systolic BP ≥160 mm Hg and/or diastolic BP was ≥110 mm Hg. The study was designed to compare 6 months of data prior to establishing the standardized protocol to data collected in the year following implementation.
During the study (including baseline and later data), there were 69,449 births, 2,034 of which had critically elevated blood pressure, preeclampsia, or superimposed preeclampsia. Compliance steadily increased over the year of the study interval. Rates of eclampsia decreased by 42.6% (1.15 ± 0.15/1000 to 0.62 ± 0.09/1000 births) and severe maternal morbidity decreased by 16.7% (2.4 ± 0.10% to 2.0 ± 0.15%) with P < .01. The authors conclude that (1) preeclampsia guideline compliance outside of studies may be low; (2) compliance can be improved quickly; (3) standardization of protocols using professional guidelines can positively impact adverse outcomes in the setting of severe preeclampsia.
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
